Therapeutic Potential of Novel Mastoparan-Chitosan Nanoconstructs Against Clinical MDR Acinetobacter baumannii: In silico, in vitro and in vivo Studies

References

• Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol. 2010;8(4):260. doi:10.1038/nrmicro2319
   PubMed Web of Science ®Google Scholar
• Dexter C, Murray GL, Paulsen IT, Peleg AY. Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev Anti Infect Ther. 2015;13(5):567–573. doi:10.1586/14787210.2015.1025055
   PubMed Web of Science ®Google Scholar
• Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409–447.
   PubMed Web of Science ®Google Scholar
• Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72(12):3277–3282. doi:10.1093/jac/dkx322
   PubMed Web of Science ®Google Scholar
• Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91. doi:10.1038/nrmicro.2017.148
   PubMed Web of Science ®Google Scholar
• Ahmed SS, Alp E, Hopman J, Voss A. Global epidemiology on colistin resistant Acinetobacter baumannii. J Infect Dis Ther. 2016.
   PubMedGoogle Scholar
• Cho YL, Yun JY, Chae SE, et al. Cephalosporin Derivatives and Pharmaceutical Compositions Thereof. Google Patents; 2017.
   Google Scholar
• Hu F-P, Guo Y, Zhu D-M, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22:S9–S14. doi:10.1016/j.cmi.2016.01.001
   PubMed Web of Science ®Google Scholar
• Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 2015;40(4):277.
   Google Scholar
• Inchai J, Pothirat C, Bumroongkit C, Limsukon A, Khositsakulchai W, Liwsrisakun C. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care. 2015;3(1):9. doi:10.1186/s40560-015-0077-4
   PubMedGoogle Scholar
• Guo X, Cao B, Wang C, Lu S, Hu XJN. In vivo photothermal inhibition of methicillin-resistant Staphylococcus aureus infection by in situ templated formulation of pathogen-targeting phototheranostics. Nanoscale. 2020;12(14):7651–7659. doi:10.1039/d0nr00181c
   PubMedGoogle Scholar
• Wang C, Zhao W, Cao B, et al. Biofilm-responsive polymeric nanoparticles with self-adaptive deep penetration for in vivo photothermal treatment of implant infection. Chem Mater. 2020;32(18):7725–7738.
   Google Scholar
• Cao B, Lyu X, Wang C, Lu S, Xing D, Hu XJB. Rational collaborative ablation of bacterial biofilms ignited by physical cavitation and concurrent deep antibiotic release. Biomaterials. 2020;262:120341. doi:10.1016/j.biomaterials.2020.120341
   PubMed Web of Science ®Google Scholar
• Xiao F, Cao B, Wen L, et al. Photosensitizer conjugate-functionalized poly (hexamethylene guanidine) for potentiated broad-spectrum bacterial inhibition and enhanced biocompatibility. Chin Chem Lett. 2020;31(9):2516–2519. doi:10.1111/jce.14669
   Google Scholar
• Gao M, Long X, Du J, et al. Enhanced curcumin solubility and antibacterial activity by encapsulation in PLGA oily core nanocapsules. Food & Function. 2020;11(1):448–455. doi:10.1039/c9fo00901a
   PubMed Web of Science ®Google Scholar
• Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol. 2016;6:194. doi:10.3389/fcimb.2016.00194
   PubMed Web of Science ®Google Scholar
• Sun E, Belanger CR, Haney EF, Hancock RE. Host defense (antimicrobial) peptides. In: Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Elsevier; 2018:253–285.
   Google Scholar
• Rossi LM, Rangasamy P, Zhang J, Qiu XQ, Wu GY. Research advances in the development of peptide antibiotics. J Pharm Sci. 2008;97(3):1060–1070. doi:10.1002/jps.21053
   PubMedGoogle Scholar
• Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15(1–2):40–56. doi:10.1016/j.drudis.2009.10.009
   PubMed Web of Science ®Google Scholar
• Vila-Farres X, De La Maria CG, López-Rojas R, Pachón J, Giralt E, Vila J. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2012;18(4):383–387. doi:10.1111/j.1469-0691.2011.03581.x
   PubMed Web of Science ®Google Scholar
• Spencer JJ, Pitts RE, Pearson RA, King LB. The effects of antimicrobial peptides WAM-1 and LL-37 on multidrug-resistant Acinetobacter baumannii. Pathog Dis. 2018;76(2):fty007. doi:10.1093/femspd/fty007
   Google Scholar
• Das Neves RC, Mortari MR, Schwartz EF, Kipnis A, Junqueira-Kipnis AP. Antimicrobial and antibiofilm effects of peptides from venom of social Wasp and scorpion on multidrug-resistant Acinetobacter baumannii. Toxins. 2019;11(4):216. doi:10.3390/toxins11040216
   PubMed Web of Science ®Google Scholar
• Peng J, Long H, Liu W, et al. Antibacterial mechanism of peptide Cec4 against Acinetobacter baumannii. Infect Drug Resist. 2019;12:2417. doi:10.2147/IDR.S214057
   PubMed Web of Science ®Google Scholar
• Neshani A, Sedighian H, Mirhosseini SA, Ghazvini K, Zare H, Jahangiri A. Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections. Microb Pathog. 2020;146:104238.
   PubMedGoogle Scholar
• Peng SY, You RI, Lai MJ, Lin NT, Chen LK, Chang KC. Highly potent antimicrobial modified peptides derived from the Acinetobacter baumannii phage endolysin LysAB2. Sci Rep. 2017;7(1):1–12. doi:10.1038/s41598-017-11832-7
   PubMedGoogle Scholar
• Howl J, Howl L, Jones S. The cationic tetradecapeptide mastoparan as a privileged structure for drug discovery: enhanced antimicrobial properties of mitoparan analogues modified at position-14. Peptides. 2018;101:95–105. doi:10.1016/j.peptides.2018.01.007
   PubMedGoogle Scholar
• Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–250. doi:10.1038/nrmicro1098
   PubMed Web of Science ®Google Scholar
• Majumder A, Biswal MR, Prakash MK. Computational screening of antimicrobial peptides for Acinetobacter baumannii. PLoS One. 2019;14(10):e0219693. doi:10.1371/journal.pone.0219693
   PubMedGoogle Scholar
• Skariyachan S, Muddebihalkar AG, Badrinath V, et al. Natural epiestriol-16 act as potential lead molecule against prospective molecular targets of multidrug resistant Acinetobacter baumannii-Insight from in silico modelling and in vitro investigations. Infect Genet Evol. 2020;82:104314.
   PubMed Web of Science ®Google Scholar
• Ramachandran B, Jeyakanthan J, Lopes BS. Molecular docking, dynamics and free energy analyses of Acinetobacter baumannii OXA class enzymes with carbapenems investigating their hydrolytic mechanisms. J Med Microbiol. 2020;69(8):1062–1078. doi:10.1099/jmm.0.001233
   PubMedGoogle Scholar
• Amera GM, Khan RJ, Pathak A, Jha RK, Muthukumaran J, Singh AK. Computer aided ligand based screening for identification of promising molecules against enzymes involved in peptidoglycan biosynthetic pathway from Acinetobacter baumannii. Microb Pathog. 2020;147:104205.
   PubMed Web of Science ®Google Scholar
• Saito H, Sakakibara Y, Sakata A, et al. Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus. PLoS One. 2019;14(5):e0217504.
   PubMed Web of Science ®Google Scholar
• Meng H, Kumar KJ. Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J Am Chem Soc. 2007;129(50):15615–15622. doi:10.1021/ja075373f
   PubMed Web of Science ®Google Scholar
• Vila-Farrés X, López-Rojas R, Pachón-Ibánez ME, et al. Sequence-activity relationship, and mechanism of action of mastoparan analogues against extended-drug resistant Acinetobacter baumannii. Eur J Med Chem. 2015;101:34–40. doi:10.1016/j.ejmech.2015.06.016
   PubMed Web of Science ®Google Scholar
• Kobsa S, Saltzman WM. Bioengineering approaches to controlled protein delivery. Pediatr Res. 2008;63(5):513. doi:10.1203/PDR.0b013e318165f14d
   PubMedGoogle Scholar
• Eslam ED, Astaneh SDA, Rasooli I, Nazarian S, Jahangiri A. Passive immunization with chitosan-loaded biofilm-associated protein against Acinetobacter baumannii murine infection model. Gene Rep. 2020;20:100708.
   Google Scholar
• Fan T, Yu X, Shen B, Sun LJ. Peptide self-assembled nanostructures for drug delivery applications. J Nanomater. 2017;2017. doi:10.1155/2017/1806461
   Google Scholar
• Brandelli A. Nanostructures as promising tools for delivery of antimicrobial peptides. Mini Rev Med Chem. 2012;12(8):731–741. doi:10.2174/138955712801264774
   PubMed Web of Science ®Google Scholar
• Fu YY, Zhang L, Yang Y, et al. Synergistic antibacterial effect of ultrasound microbubbles combined with chitosan-modified polymyxin B-loaded liposomes on biofilm-producing Acinetobacter baumannii. Int J Nanomed. 2019;14:1805. doi:10.2147/IJN.S186571
   PubMed Web of Science ®Google Scholar
• Tamara F, Lin C, Mi FL, Ho YC. Antibacterial effects of chitosan/cationic peptide nanoparticles. Nanomaterials. 2018;8(2):88. doi:10.3390/nano8020088
   Web of Science ®Google Scholar
• Pourhajibagher M, Hosseini N, Boluki E, Chiniforush N, Bahador AJ. Photoelimination potential of chitosan nanoparticles-indocyanine green complex against the biological activities of Acinetobacter baumannii strains: a preliminary in vitro study in burn wound infections. J Lasers Med Sci. 2020;11(2):187.
   PubMedGoogle Scholar
• International Council for Harmonisation. ICH guidelines. homepage on internet; 2019. Available from: http://www.ich.org/products/guidelines/safety/article/safety-guidelines.html. Accessed April 2, 2021.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Twenty-second Informational supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey R, et al. Multidrug‐resistant, extensively drug‐resistant and pandrug‐resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2016–2: Maestro. New York, NY: Schrödinger, LLC; 2017.
   Google Scholar
• Schrödinger Release 2016–3: MacroModel. New York, NY: Schrödinger, LLC; 2016.
   Google Scholar
• Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a visualization system for exploratory research and analysis. J Computat Chem. 2004;25(13):1605–1612. doi:10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2017–3: Desmond molecular dynamics system. New York, NY: DE Shaw Research; 2017.
   Google Scholar
• Chemical Computing Group. Molecular operating environment (MOE). Montreal: Chemical Computing Group Inc; 2016.
   Google Scholar
• DeLano WL. The PyMOL Molecular Graphics System. San Carlos, CA: Delano Scientific; 2002.
   Google Scholar
• Razzaq A, Shamsi S, Ali A, et al. Microbial proteases applications. Front Bioeng Biotechnol. 2019;7:110. doi:10.3389/fbioe.2019.00110
   PubMed Web of Science ®Google Scholar
• Stank A, Kokh DB, Fuller JC, Wade RC. Protein binding pocket dynamics. Acc Chem Res. 2016;49(5):809–815. doi:10.1021/acs.accounts.5b00516
   PubMed Web of Science ®Google Scholar
• Volkamer A, Kuhn D, Rippmann F, Rarey M. DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics. 2012;28(15):2074–2075. doi:10.1093/bioinformatics/bts310
   PubMed Web of Science ®Google Scholar
• Piras AM, Maisetta G, Sandreschi S, et al. Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis. Front Microbiol. 2015;6:372. doi:10.3389/fmicb.2015.00372
   PubMed Web of Science ®Google Scholar
• Wiegand I, Hilpert K, Hancock RE. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nature Protocols. 2008;3(2):163. doi:10.1038/nprot.2007.521
   PubMed Web of Science ®Google Scholar
• Coleman RG, Sharp KA. Protein pockets: inventory, shape, and comparison. J Chem Informat Model. 2010;50(4):589–603. doi:10.1021/ci900397t
   PubMed Web of Science ®Google Scholar
• Uddin R, Rafi S. Structural and functional characterization of a unique hypothetical protein (WP_003901628. 1) of Mycobacterium tuberculosis: a computational approach. Med Chem Res. 2017;26(5):1029–1041.
   Google Scholar
• Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal. 2016;6(2):71–79. doi:10.1016/j.jpha.2015.11.005
   PubMed Web of Science ®Google Scholar
• Mei L, Xu Z, Shi Y, et al. Multivalent and synergistic chitosan oligosaccharide-Ag nanocomposites for therapy of bacterial infection. Sci Rep. 2020;10(1):1–9.
   PubMedGoogle Scholar
• Mei L, Zhang X, Wang Y, et al. Multivalent polymer–Au nanocomposites with cationic surfaces displaying enhanced antimicrobial activity. Polym Chem. 2014;5(8):3038–3044. doi:10.1038/ncomms4038
   Web of Science ®Google Scholar
• Sultan I, Rahman S, Jan AT, Siddiqui MT, Mondal AH, Haq QMR. Antibiotics, resistome and resistance mechanisms: a bacterial perspective. Front Microbiol. 2018;9:2066. doi:10.3389/fmicb.2018.02066
   PubMed Web of Science ®Google Scholar
• Cruz J, Ortiz C, Guzman F, Fernandez-Lafuente R, Torres R. Antimicrobial peptides: promising compounds against pathogenic microorganisms. Curr Med Chem. 2014;21(20):2299–2321. doi:10.2174/0929867321666140217110155
   PubMedGoogle Scholar
• Bechinger B, Gorr S-U. Antimicrobial peptides: mechanisms of action and resistance. J Dent Res. 2017;96(3):254–260. doi:10.1177/0022034516679973
   PubMed Web of Science ®Google Scholar
• Liu H, Du Y, Wang X, Sun L. Chitosan kills bacteria through cell membrane damage. Int J Food Microbiol. 2004;95(2):147–155. doi:10.1016/j.ijfoodmicro.2004.01.022
   PubMed Web of Science ®Google Scholar
• Biswaro LS, da Costa Sousa MG, Rezende T, Dias SC, Franco OL. Antimicrobial peptides and nanotechnology, recent advances and challenges. Front Microbiol. 2018;9:855. doi:10.3389/fmicb.2018.00855
   PubMed Web of Science ®Google Scholar
• Zha RH, Sur S, Stupp SI. Self‐assembly of cytotoxic peptide amphiphiles into supramolecular membranes for cancer therapy. Adv Healthcare Mater. 2013;2(1):126–133. doi:10.1002/adhm.201200118
   Google Scholar
• Qi L, Xu Z, Jiang X, Hu C, Zou X. Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res. 2004;339(16):2693–2700. doi:10.1016/j.carres.2004.09.007
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787. doi:10.1038/nri2868
   PubMed Web of Science ®Google Scholar
• Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Trop J Pharm Res. 2013;12(2):265–273.
   Google Scholar
• Landriscina A, Rosen J, Friedman AJ. Biodegradable chitosan nanoparticles in drug delivery for infectious disease. Nanomedicine. 2015;10(10):1609–1619. doi:10.2217/nnm.15.7
   PubMed Web of Science ®Google Scholar
• Costa E, Silva S, Vicente S, Veiga M, Tavaria F, Pintado M. Chitosan as an effective inhibitor of multidrug resistant Acinetobacter baumannii. Carbohydr Polym. 2017;178:347–351. doi:10.1016/j.carbpol.2017.09.055
   PubMedGoogle Scholar
• Cobrado L, Azevedo M, Silva-Dias A, Ramos JP, Pina–Vaz C, Rodrigues AJ. Cerium, chitosan and hamamelitannin as novel biofilm inhibitors? J Antimicrob Chemother. 2012;67(5):1159–1162. doi:10.1093/jac/dks007
   PubMedGoogle Scholar
• Harris G, KuoLee R, Xu HH, Chen W. Mouse models of Acinetobacter baumannii infection. Curr Protoc Microbiol. 2017;46(1):6G. 3.1–6G. 3.23. doi:10.1002/cpmc.36
   Google Scholar
• Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol. 2008;46(8):2499–2507. doi:10.1128/JCM.00367-08
   PubMed Web of Science ®Google Scholar
• Jacobs AC, Thompson MG, Black CC, et al. AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. MBio. 2014;5(3). doi:10.1128/mBio.01076-14
   Google Scholar